Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)

The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alteratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Kazuko, Takahama, Takayuki, Shimokawa, Mototsugu, Azuma, Koichi, Takeda, Masayuki, Kato, Terufumi, Daga, Haruko, Okamoto, Isamu, Akamatsu, Hiroaki, Teraoka, Shunsuke, Ono, Akira, Ohira, Tatsuo, Yokoyama, Toshihide, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko, Nishio, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782093/
https://www.ncbi.nlm.nih.gov/pubmed/33131198
http://dx.doi.org/10.1002/1878-0261.12841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782093/
https://www.ncbi.nlm.nih.gov/pubmed/33131198
http://dx.doi.org/10.1002/1878-0261.12841

Ejemplares similares